Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On ...
SciELO

Management of parotidectomy with facial nerve preservation for the treatment of pleomorphic adenoma of the parotid gland

Objectives Facial paralysis is recognized as the most prevalent complication following parotidectomy. This study aimed to evaluate the symptoms and post-operative complications of parotidectomy while ...
Frontiers

Case Report: Pleomorphic adenoma of the breast: diagnostic pitfalls and a novel PLAG1::FTO fusion

Pleomorphic adenoma (PA) of the breast and its malignant transformation represent extremely rare clinical entities, and the molecular alterations underlying this tumor type remain largely ...
Targeted Oncology

Lifileucel Demonstrates 50% ORR in Advanced Soft Tissue Sarcomas

A 50% confirmed ORR in early evaluable UPS/DDLPS cases contrasts with historical second-line benchmarks of <5% ORR, mPFS ~2–3 months, and mOS ~9–10 months. Treatment consists of one-time lifileucel ...

Iovance Biotherapeutics explodes over 20% — early trial data sparks investor frenzy

Iovance Biotherapeutics IOVA shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas. This ...

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.